Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Marbury TC"" wg kryterium: Autor


Tytuł:
Pharmacokinetics and safety of a single oral dose of once-daily alfuzosin, 10 mg, in male subjects with mild to severe renal impairment.
Autorzy:
Marbury TC
Blum RA
Rauch C
Pinquier J
Pokaż więcej
Źródło:
Journal of Clinical Pharmacology; Dec2002, Vol. 42 Issue 12, p1311-1317, 7p
Czasopismo naukowe
Tytuł:
Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators.
Autorzy:
Larochelle P (AUTHOR)
Flack JM (AUTHOR)
Marbury TC (AUTHOR)
Sareli P (AUTHOR)
Krieger EM (AUTHOR)
Reeves RA (AUTHOR)
Larochelle, P (AUTHOR)
Flack, J M (AUTHOR)
Marbury, T C (AUTHOR)
Sareli, P (AUTHOR)
Krieger, E M (AUTHOR)
Reeves, R A (AUTHOR)
Pokaż więcej
Źródło:
American Journal of Cardiology. 1997 Dec 15, Vol. 80 Issue 12, p1613-1615. 3p.
Czasopismo naukowe
Tytuł:
Pharmacokinetics of Gepotidacin in Subjects With Normal Hepatic Function and Hepatic Impairment.
Autorzy:
Hossain M; GlaxoSmithKline, Collegeville, Pennsylvania, USA.
Tiffany C; GlaxoSmithKline, Collegeville, Pennsylvania, USA.
Tao Y; GlaxoSmithKline, Collegeville, Pennsylvania, USA.
Barth A; GlaxoSmithKline, Collegeville, Pennsylvania, USA.
Marbury TC; Orlando Clinical Research Center, Orlando, Florida, USA.
Preston RA; Clinical Pharmacology Research Unit, Division of Clinical Pharmacology University of Miami, Department of Medicine, Miller School of Medicine, University of Miami Clinical and Translational Science Institutes (CTSI) and The Peggy and Harold Katz Family Drug Discovery Center, Miami, Florida, USA.
Dumont E; GlaxoSmithKline, Collegeville, Pennsylvania, USA.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2021 Jun; Vol. 10 (6), pp. 588-597. Date of Electronic Publication: 2021 Jan 15.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
MeSH Terms:
Acenaphthenes/*administration & dosage
Anti-Bacterial Agents/*administration & dosage
Heterocyclic Compounds, 3-Ring/*administration & dosage
Liver Diseases/*physiopathology
Acenaphthenes/adverse effects ; Acenaphthenes/pharmacokinetics ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents/adverse effects ; Anti-Bacterial Agents/pharmacokinetics ; Area Under Curve ; Female ; Half-Life ; Heterocyclic Compounds, 3-Ring/adverse effects ; Heterocyclic Compounds, 3-Ring/pharmacokinetics ; Humans ; Male ; Middle Aged ; Severity of Illness Index ; Young Adult
Czasopismo naukowe
Tytuł:
A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment.
Autorzy:
Ou YC; BeiGene USA, Inc, San Mateo, CA, USA.
Preston RA; Department of Medicine, Division of Pharmacology, Miller School of Medicine, University of Miami, Coral Gables, FL, USA.
Marbury TC; Orlando Clinical Research Center, Orlando, FL, USA.
Tang Z; BeiGene USA, Inc, San Mateo, CA, USA.
Novotny W; BeiGene USA, Inc, San Mateo, CA, USA.
Tawashi M; BeiGene USA, Inc, San Mateo, CA, USA.
Li TK; BeiGene USA, Inc, San Mateo, CA, USA.
Sahasranaman S; BeiGene USA, Inc, San Mateo, CA, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2020 Jun; Vol. 61 (6), pp. 1355-1363. Date of Electronic Publication: 2020 Feb 07.
Typ publikacji:
Clinical Trial, Phase I; Journal Article
MeSH Terms:
Liver Diseases*/complications
Liver Diseases*/diagnosis
Pyrimidines*
Area Under Curve ; Humans ; Piperidines ; Pyrazoles
Czasopismo naukowe
Tytuł:
Pharmacokinetics and Immunogenicity of ASP0113 in CMV-Seronegative Dialysis Patients and CMV-Seronegative and -Seropositive Healthy Subjects.
Autorzy:
Bonate PL; Astellas Pharma Global Development, Inc, Northbrook, Illinois, USA.
Van Sant C; Astellas Research Institute of America, Northbrook, Illinois, USA.
Cho K; Astellas Pharma Global Development, Inc, Northbrook, Illinois, USA.
Zook EC; Astellas Pharma Global Development, Inc, Northbrook, Illinois, USA.
Smith LR; Vical Inc, San Diego, California, USA.
Boutsaboualoy S; Vical Inc, San Diego, California, USA.
Ye M; Vical Inc, San Diego, California, USA.
Wang X; Astellas Pharma Global Development, Inc, Northbrook, Illinois, USA.
Wu R; Astellas Pharma Global Development, Inc, Northbrook, Illinois, USA.
Koester A; Parexel International, Baltimore, Maryland, USA.
Rammelsberg D; Randstad Pharma, Deerfield, Illinois, USA.
Goldwater R; Parexel International, Baltimore, Maryland, USA.
Marbury TC; Orlando Clinical Research Center, Orlando, Florida, USA.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2020 May; Vol. 9 (4), pp. 444-455. Date of Electronic Publication: 2020 Mar 23.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Cytomegalovirus Infections*/chemically induced
Cytomegalovirus Infections*/prevention & control
Vaccines, DNA*/adverse effects
Cytomegalovirus ; Healthy Volunteers ; Humans ; Phosphoproteins ; Renal Dialysis
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies